Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H4COVID trial of sodium thiosulfate in critically ill COVID-19 patients
2022-000642-16Phase 2Completed
- Sponsor
- Hellenic Institute for the Study of Sepsis
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sodium thiosulfate in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Hellenic Institute for the Study of Sepsis. Primary endpoint: Treatment-emergent serious and non-serious adverse events. Started Feb 2022; status: completed.
02
Drugs
sodium thiosulfate
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2022-000642-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000642-16.